Navigation Links
Novavax Announces New Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
Date:3/26/2009

ROCKVILLE, Md., March 26 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it will report its 2008 fourth quarter financial results in a press release to be issued after 2:00 p.m. Eastern Time on March 31, 2009. The Company will hold an investor conference call to discuss its financial results at 4:00 p.m. Eastern Time on March 31, 2009. The call will be hosted by Novavax President and Chief Executive Officer Dr. Rahul Singhvi and other members of senior management. A question and answer session will follow the financial results overview. The dial-in number for the conference call is USA and Canada (866) 793-1341 International: (703) 639-1312.

A live audio webcast of the conference call will be available at www.novavax.com. Please connect to this website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast. A replay of the webcast will be available for 90 days after the webcast and a replay of the conference call will also be available by telephone beginning 1pm ET. March 31, 2009 through midnight April 2, 2009. To access the replay, dial (888) 266-2081 and enter pass code 1334845.

About Novavax, Inc.

Novavax, Inc. is a clinical stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent, recombinant vaccines utilizing new and efficient manufacturing approaches. Additional information about Novavax is available at www.novavax.com and in the Company's various filings with the Securities and Exchange Commission.

Forward Looking Statements

Statements herein relating to future development results and performance, conditions or strategies and other matters, including expectations regarding product and clinical developments, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks relating to the early stage of Novavax's product candidates under development; current results may not be predictive of future pandemic results, results of our seasonal influenza vaccine or any other vaccine that we may develop; further testing is required before regulatory approval can be applied for and the FDA may not approve a vaccine even if further trial results are similar to those disclosed previously by the company; uncertainties relating to clinical trials, including possible delays in initiating or completing the trials and safety and efficacy results; dependence on the efforts of third parties; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility; and risks that we may lack the financial resources and access to capital to fund our operations including further clinical trials. Further information on the factors and risks that could affect Novavax's business, financial conditions and results of operations, is contained in Novavax's filings with the U.S. Securities and Exchange Commission, which are available at http://www.sec.gov. These forward-looking statements speak only as of the date of this press release, and Novavax assumes no duty to update forward-looking statements.


'/>"/>
SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Novavax Announces Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
2. Novavax to Present at Cowen and Company 29th Annual Healthcare Conference
3. NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate Directed Against the Fusion (F) Protein
4. Novavax and Vivalis Sign a Research License Agreement to Use the EB66(R) Cell Line for the Production of Virus Like Particle Based Vaccines
5. Novavax Announces Operational Status of Its Vaccine Pilot Plant and Commercial Launch Facility
6. Novavax CMO to Present at Phacilitate Vaccine Forum Washington 2009
7. NOVAVAX and the University of Massachusetts Medical School Announce Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate
8. Novavax to Present Seasonal Influenza Data Results in an Investor Conference Call on December 11, 2008
9. Novavax CEO to Present at Piper Jaffray 20th Annual Healthcare Conference
10. Novavax CEO to Present at Lazard Capital Markets 5th Annual Healthcare Conference
11. Novavax Announces Release Date of 2008 Third Quarter Financial Results and Investor Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... -- Four US Biotech equities have been ... are: Anthera Pharmaceuticals Inc. (NASDAQ: ANTH), Arrowhead Pharmaceuticals Inc. ... and Conatus Pharmaceuticals Inc. (NASDAQ: CNAT ). ... are growing more bullish on the sector as a ... cash held overseas for tax reason by large US ...
(Date:2/27/2017)... ... ... The Catalyst Midwest premix manufacturing facility has been certified as organic, ... label organic services. , The first organic product is Organic 18 Percent Layer Feed, ... Marketing, which owns the facility. , Catalyst already has received the Safe Feed/Safe ...
(Date:2/24/2017)... SAN FRANCISCO, CA (PRWEB) , ... February 24, 2017 , ... ... awarding of a $224K grant from the National Institute of Mental Health (NIMH) for ... is based on Delpor’s PROZOR technology and is expected to deliver therapeutic ...
(Date:2/24/2017)... , Feb. 24, 2017 Symic Bio, a ... a new category of therapeutics, announced today the completion ... in peripheral artery disease. The trial will evaluate the ... therapeutic, in the reduction of restenosis following angioplasty. ... development milestone for SB-030," said Nathan Bachtell , ...
Breaking Biology Technology:
(Date:2/3/2017)... , Feb. 3, 2017 A new ... Identity Strategy Partners, LLP (IdSP) . Designed to fill ... the complex identity market, founding partners Mark Crego ... 35 combined years just in identity expertise that span ... and non-profit leadership. The Crego-Kephart combined expertise has a ...
(Date:2/2/2017)... YORK , Feb. 2, 2017  EyeLock LLC, ... released a new white paper " What You Should ... The problem of ensuring user authenticity is a growing ... the authentication of users. However, traditional authentication schemes such ... Biometric authentication offers an elegant solution ...
(Date:2/1/2017)... 1, 2017 IDTechEx Research, a leading provider ... announces the availability of a new report, Sensors for Robotics: ... Continue Reading ... ... robots. Source: IDTechEx Report "Sensors for Robotics: Technologies, Markets and Forecasts ...
Breaking Biology News(10 mins):